What's in Sumitomo Pharma America, Inc.'s pipeline?

Sumitomo Pharma America, Inc. has 36 drugs in our index: 4 marketed, 0 filed, 15 in Phase 3, 5 in Phase 2, 12 in Phase 1.

Which companies overlap with Sumitomo Pharma America, Inc.'s portfolio?

Top competitors by shared drug class: AstraZeneca, GlaxoSmithKline, Teva Branded Pharmaceutical Products R&D, Inc., Organon and Co, Sanofi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sumitomo-pharma-america-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sumitomo Pharma America, Inc. — Portfolio Competitive Intelligence Brief

Sumitomo Pharma America, Inc. pipeline: 4 marketed, 0 filed, 15 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 15 Phase 3 5 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Arformoterol Tartrate Inhalation Solution	Arformoterol Tartrate Inhalation Solution	marketed	Long-acting beta-2 adrenergic agonist (LABA)	Beta-2 adrenergic receptor	Respiratory / Pulmonology
Eszopiclone (Lunesta)	Eszopiclone (Lunesta)	marketed	Nonbenzodiazepine hypnotic (Z-drug)	GABA-A receptor (alpha-1 subunit)	Neurology / Sleep Medicine
ciclesonide nasal aerosol	ciclesonide nasal aerosol	marketed	Intranasal corticosteroid	Glucocorticoid receptor	Allergy/Immunology
Arformoterol and Tiotropium	Arformoterol and Tiotropium	marketed
Formoterol 12 ųg BID	Formoterol 12 ųg BID	phase 3	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor	Respiratory
mometasone nasal inhalation	mometasone nasal inhalation	phase 3	Corticosteroid		Respiratory
Levalbuterol tartrate HFA MDI	Levalbuterol tartrate HFA MDI	phase 3	Beta-2 adrenergic receptor agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor	Respiratory
Lurasidone 20, 40, 60, 80 mg, flexibly dosed	Lurasidone 20, 40, 60, 80 mg, flexibly dosed	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor	Psychiatry
racemic albuterol MDI	racemic albuterol MDI	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor	Respiratory
Arformoterol 25 ųg BID	Arformoterol 25 ųg BID	phase 3	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor	Respiratory
Racemic Albuterol	Racemic Albuterol	phase 3	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor	Respiratory
Salmeterol MDI	Salmeterol MDI	phase 3	Long-acting beta-2 agonist (LABA)	Beta-2 adrenergic receptor	Respiratory

Therapeutic area mix

Respiratory · 10
Psychiatry · 2
Neurology · 2
Other · 2
Allergy/Immunology · 1
Respiratory/Immunology · 1
Hematology · 1
Neurology / Sleep Medicine · 1
Respiratory / Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 6 shared drug classes
GlaxoSmithKline · 6 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 5 shared drug classes
Organon and Co · 4 shared drug classes
Sanofi · 4 shared drug classes
Children's Hospital of Philadelphia · 2 shared drug classes
Chiesi Farmaceutici S.p.A. · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sumitomo Pharma America, Inc.:

Cite this brief

Drug Landscape (2026). Sumitomo Pharma America, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sumitomo-pharma-america-inc. Accessed 2026-05-16.